RESEARCH
Current Projects
At the Institute of Cancer and Stem Cell Research (ICSR), we are dedicated to advancing the field of cancer biology, stem cell research, and regenerative medicine. Our research projects are at the forefront of scientific innovation, focusing on understanding the molecular mechanisms of cancer and developing novel therapies.
This project aims to isolate, culture, and characterize primary cancer cell lines directly from patient tumors, providing a more accurate model of cancer biology. By focusing on patient-derived cell lines, particularly from rare and under-researched cancers such as solid tumors and hematologic malignancies, we enable more precise disease modeling.
These primary cell lines are essential for studying cancer at the molecular level, evaluating drug responses, and screening potential therapeutic compounds. Unlike conventional immortalized cell lines, primary cell lines better represent the complexities of real tumors, making them invaluable for advancing personalized medicine and accelerating the development of targeted therapies. Through this work, ICSR aims to enhance cancer research, leading to more effective, patient-specific treatment strategies that improve clinical outcomes.
Primary Cell Lines
Stem Cell Therapy
This project aims to harness stem cell-based therapies to develop innovative cancer treatments. By leveraging mesenchymal stem cells (MSCs) and induced pluripotent stem cells (iPSCs), the research focuses on engineering stem cells to specifically target tumors, deliver therapeutic agents, and modulate immune responses.
Current studies include the use of CAR T-cell therapy and immune-modulation techniques to enhance the body’s ability to fight cancer. The goal is to create treatments that are both highly effective and less toxic compared to conventional chemotherapy and radiotherapy. If successful, this research could revolutionize cancer therapy by providing targeted, personalized treatments that improve patient outcomes and quality of life.
This project seeks to enhance cancer immunotherapy by targeting the tumor microenvironment (TME), a key factor in tumor growth, progression, and treatment resistance. Researchers aim to understand the interactions between cancer cells and TME components, including immune cells, fibroblasts, and the extracellular matrix.
The focus is on reprogramming the TME to support immune responses and counteract immune-suppressive mechanisms. By modifying the TME, the project aims to increase the efficacy of existing immunotherapies and pave the way for novel therapeutic strategies. If successful, this work could lead to significant advancements in cancer treatment, improving outcomes for patients and reducing resistance to therapies.